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Background: Exacerbation frequency is related to disease progression, quality of life, and prognosis in
COPD. Earlier diagnosis, along with interventions aimed at preventing exacerbations and delaying pro-
gression, may help reduce the global burden of disease. Long-acting inhaled bronchodilators are effective
at maintaining symptom relief and are recommended as ﬁrst-choice therapy for more symptomatic
patients and those at risk of exacerbation.
Methods: As prevention of exacerbations is a priority goal in COPD management and a number of
different long-acting bronchodilators are available, we conducted a systematic review of exacerbation
data from randomized controlled trials (published January 2000 to May 2014) comparing the effect of
tiotropium versus placebo and/or other maintenance therapies.
Results: Exacerbations were a primary endpoint in 12 publications (ﬁve studies: four comparing tio-
tropium with placebo; one with active comparator) and a secondary endpoint in 17 publications (seven
studies: six comparing tiotropium with placebo; one with active comparator). Overall, tiotropium was
associated with a longer time to ﬁrst exacerbation event and fewer exacerbations (including severe
exacerbations/hospitalizations) compared with placebo and long-acting b2-agonists. Tiotropium also
showed similar efﬁcacy to glycopyrronium and a ﬁxed long-acting muscarinic antagonist/long-acting b2-
agonist combination (glycopyrronium/indacaterol), although not all studies were powered to demon-
strate differences in exacerbation outcomes. Exacerbation outcomes were comparable with both for-
mulations of tiotropium (HandiHaler® 18 mg/Respimat® 5 mg).
Conclusions: The results of this comprehensive systematic review demonstrate tiotropium is beneﬁcial in
reducing exacerbation risk versus placebo or other maintenance treatments.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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COPD is characterized by airﬂow obstruction, and bronchodila-
tors are central to its management [1]. The aims of pharmacological
therapy for COPD are to prevent and control symptoms, reduce the
frequency and severity of exacerbations, and improve health status
and exercise tolerance [1]. Short-acting bronchodilators can pro-
duce substantial improvements in lung function, but long-acting
bronchodilators are more effective at maintaining symptom relief
[1]. Improvements in FEV1 produced by bronchodilation correlate
with improvements in breathlessness and health status as well as
reduced exacerbation rates [2].
Exacerbations are an important component of COPD [3,4],
signiﬁcantly impacting on the burden of disease [5], leading to a
worsening health status and increased risk of future exacerbations
and death [6,7]. Exacerbations are also strong predictors of disease
progression, quality of life, and prognosis [7,8]. Some patients may
be more prone to exacerbations [4], and the prevention of exacer-
bations is a priority goal in COPD management [1].
Current maintenance therapies for patients at risk of exacerba-
tions include long-acting anticholinergics (also called long-acting
muscarinic antagonists [LAMAs]), long-acting b2-agonists (LABAs),
LABAs combined with inhaled corticosteroids (ICS), and phospho-
diesterase type 4 inhibitors [9,10]. For patients at risk of exacerba-
tions in the Global Initiative for Chronic Obstructive Lung Disease
(GOLD) groups C and D, a long-acting anticholinergic or a ﬁxed
combination of ICS/LABA is recommended as ﬁrst-choice therapy
[10], while for symptomatic patients at lower risk of exacerbations
(group B), a LAMA or LABA is recommended. There is now more
evidence to inform these choices, and we have therefore undertaken
a systematic review of the effects of tiotropium therapy compared
with placebo and/or other maintenance therapies in patients with
COPD. Unlike other publications (for example, Karner, et al. [11]), this
review includes for the ﬁrst time all published randomized
controlled trials with exacerbation outcomes as prespeciﬁed end-
points and with tiotropium as an active treatment arm.
Tiotropium is a once-daily LAMA shown to reduce exacerbations
and improve other important outcomes of COPD [12e15]. Tio-
tropium is approved and marketed as a dry-powder formulation
delivered via the HandiHaler® device (18 mg; Boehringer Ingelheim
Pharma GmbH and Co KG, Ingelheim am Rhein, Germany) [16] and
as an aqueous solution delivered via the Respimat® inhaler (5 mg;
two puffs of 2.5 mg once daily; Boehringer Ingelheim Pharma GmbH
and Co KG, Ingelheim am Rhein, Germany) in many countries [17].2. Methods
A systematic literature search (January 2000 to May 2014) ofelectronic databases was conducted to identify all COPD trials in
which exacerbations were a prespeciﬁed endpoint and tiotropium
was an active treatment arm. As there is no standardized deﬁnition
of a COPD exacerbation due to the heterogeneity of causes, symp-
toms and severities [18], our literature search did not limit studies
to a speciﬁc deﬁnition. (For deﬁnitions of exacerbation used in
selected studies, see Table E1 in the online supplement.) The total
hits from the search were assessed for their relevance (based on
titles/abstracts), and publications that were deemed potentially
relevant were obtained in full and assessed.
Articles were included if they reported on double-blind, ran-
domized, controlled trials of 6 months' duration. Both placebo-
and active-controlled (i.e., vs. other maintenance therapies) trials
were eligible if exacerbation data were included as a primary or
secondary endpoint; blinded studies with additional open-label
tiotropium arm(s) were included if appropriate. Prospective
studies and subgroup analyses of trials were permitted, provided
the data were new and not duplicated elsewhere. Non-blinded
open-label studies, review articles, methodology papers, retro-
spective studies, pooled analyses, case studies, conference ﬁndings,
congress abstracts, pharmacoeconomic studies, and meeting re-
ports were excluded. The search was limited to trials in humans.
The literature search results and article selection were reviewed
and veriﬁed by the authors to ensure their accuracy.
Exacerbation outcomes included time to ﬁrst event (exacerba-
tion/hospitalization due to exacerbation), exacerbation rate, and
the proportion of patients with events (exacerbations/hospitaliza-
tions due to exacerbation).3. Results
3.1. Summary of search ﬁndings
The search returned a total of 236 hits (Fig. 1). Of these, 195
publications were excluded based on the title/abstract and identi-
ﬁcation of duplicates. The remaining 41 publications were deemed
potentially relevant based on the title and/or abstract. Of these, a
further 14 publications were excluded based on duration of study
(i.e., <6 months [n ¼ 6]), retrospective nature of study (n ¼ 1), non-
appropriate comparator (n ¼ 1), open-label study (n ¼ 2), pooled
analysis (n¼ 3), and lack of data on speciﬁc treatments (n¼ 1). Two
additional recent publications were identiﬁed during the search
[19,20]. In total, 29 publications were deemed relevant for inclusion
in the ﬁnal analysis [12,14,15,19e44]. Refer to online supplement,
Tables E2 and E3, for details of study durations and population size.
Exacerbations were a primary study endpoint (including sub-
group analyses and prospective studies) in 12 publications
[12,15,21,23,24,30,35,37,38,42e44] and a secondary study endpoint
Fig. 1. Systematic review of published manuscripts reporting exacerbation data in trials comparing tiotropium with placebo and/or other maintenance therapies. a Two additional
articles included following a ﬁnal check on any relevant, recently published articles (since May 2014 end of search period and submission date).
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lications [14,19,20,22,25e29,31e34,36,39].
Six studies included an entry criterion that patients must have
had one or more exacerbations in the year prior to entry
[15,21,29,30,42e44], and one study required one or more exacer-
bations in the 2 years prior to entry [26].
The exacerbation data reported included time to ﬁrst event,
exacerbation rate, and proportion of patients with an event (online
supplement, Tables E2 and E3); severe (hospitalized) exacerbation
data have been detailed where available. Of the 209 publications
that were excluded, 26 reported exacerbations as “other endpoint”.
Additional data from open-label comparisons are included for in-
formation only [43,45,46].3.2. Effect of tiotropium versus placebo
Sixteen publications comparing tiotropium with placebo
investigated the use of HandiHaler® (18 mg)
[14,24e28,30e32,34e37,39e41], and four reported the effects of
Respimat® (5 mg [two puffs of 2.5 mg once daily] and/or 10 mg)
[12,22,23,38].3.2.1. Time to ﬁrst exacerbation event
There were 14 publications (including subgroup analyses) that
compared tiotropium with placebo, with time to ﬁrst exacerbation
as the endpoint [12,14,22e25,27,28,30,35,36,38,40,41]. Tiotropium
was associatedwith a signiﬁcantly (p< 0.05) prolonged time to ﬁrst
exacerbation in nine studies [12,14,23e25,30,35,36,40] (online
supplement, Table E2). In three studies, the time to ﬁrst hospitali-
zation (severe exacerbation) was also signiﬁcantly (p < 0.05) pro-
longed in patients treated with tiotropium compared with placebo
(Fig. 2; online supplement, Table E2) [12,14,35].3.2.2. Exacerbation rate or proportion of patients with
exacerbations
Twenty publications (including subgroup analyses) compared
the effect of tiotropium with placebo on the rate of exacerbations
or proportion of patients experiencing an exacerbation event
[12,14,22e28,30e32,34e41]. Fewer patients treated with tio-
tropium experienced one or more exacerbations
[12,23e25,30,35e38]; these differences reached statistical sig-
niﬁcance in nine publications [12,23e25,30,35e38]. In
addition, the number/rate of exacerbations
[14,22e25,27,28,30e32,34,36e40] and exacerbation days
[14,24,30,36,37,40] were reduced and the probability of remain-
ing exacerbation-free [23] was higher in patients receiving tio-
tropium versus placebo.
In total, 16 publications examined the effect of tiotropium on
severe exacerbations or hospitalizations due to an exacerbation
[12,14,23e28,30,31,34e37,39,41]; in ﬁve studies, signiﬁcantly
fewer patients experienced a severe/hospitalized exacerbation in
the tiotropium arms versus placebo [24,25,35,37,39]. In addition,
two studies [24,25] demonstrated that patients receiving tio-
tropium had signiﬁcantly fewer hospitalization days due to a severe
exacerbation versus those receiving placebo (online supplement,
Table E2). However, in two studies [14,26], the number of hospi-
talizations and hospitalization days due to a severe exacerbation
did not differ between tiotropium and placebo (online supplement,
Table E2).
3.2.3. Subgroup analyses
In general, the eight subgroup analyses comparing tiotropium
with placebo displayed similar trends for exacerbation reductions
to those observed in the primary studies, although not all outcomes
were statistically signiﬁcant [27,28,31,32,34,37e39]. In prespeciﬁed
subgroup analyses of the Understanding Potential Long-term
Fig. 2. Hazard ratios for an exacerbation of COPD in patients receiving tiotropium versus placebo.
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signiﬁcantly reduced the rate of exacerbations in patients with
COPD aged <50 years (p ¼ 0.02) [34]. Tiotropium reduced the
number of exacerbations per patient-year by 16% versus control in
patients naïve to maintenance therapy prior to the study; however,
this failed to reach statistical signiﬁcance (p ¼ 0.08) [41].
In a post-hoc subanalysis of the Veteran Affairs Study (despite
not being adequately powered), tiotropium reduced the likelihood
of having at least one exacerbation versus placebo in the entire
patient group (rate ratio [95% conﬁdence interval (CI)]: 0.81
[0.66e0.99]; p ¼ 0.037), with no statistically signiﬁcant difference
between the African American and Caucasian subgroups (p ¼ 0.34)
[37].3.3. Effect of tiotropium versus active comparators
3.3.1. Tiotropium monotherapy versus salmeterol
Two publications (including subgroup analyses) directly
compared tiotropium with salmeterol [15,42]. In the Prevention Of
Exacerbations with Tiotropium in COPD (POET-COPD®) trial, tio-
tropium signiﬁcantly prolonged the time to ﬁrst exacerbation (187
vs. 145 days; hazard ratio [HR] [95% CI], 0.83 [0.77e0.90]; p < 0.001)
and severe exacerbation (HR [95% CI], 0.72 [0.61e0.85]; p < 0.001)
in patients with moderate to very severe COPD when compared
with salmeterol [15] (Fig. 3; online supplement, Table E3).
In addition, tiotropium reduced the annual rate of exacerbations
versus salmeterol (0.64 vs. 0.72; rate ratio [95% CI], 0.89
[0.83e0.96]; p ¼ 0.002), as well as the annual rate of moderate
exacerbations (0.54 vs. 0.59; rate ratio [95% CI], 0.93 [0.86e1.00];
p ¼ 0.048) and severe exacerbations (0.09 vs. 0.13; rate ratio [95%
CI], 0.73 [0.66e0.82]; p < 0.001) (online supplement, Table E3). Of
those patients who experienced an exacerbation in this trial, 44%
had moderate (GOLD stage 2) COPD at trial onset.In subgroup analyses of POET-COPD®, tiotropium signiﬁcantly
prolonged the time to ﬁrst exacerbation (HR [95% CI], 0.88
[0.79e0.99]; p ¼ 0.028) and ﬁrst severe exacerbation (HR [95% CI],
0.66 [0.48e0.91]; p ¼ 0.012), reduced rates of severe exacerbations
(rate ratio [95% CI], 0.70 [0.57e0.85]; p < 0.001) in GOLD stage 2
patients [42], signiﬁcantly prolonged the time to ﬁrst exacerbation
(HR [95% CI], 0.79 [0.65e0.97; p ¼ 0.028), and reduced the annual
exacerbation rate (rate ratio [95% CI], 0.77 [0.63e0.94]; p ¼ 0.012)
in maintenance therapy-naïve patients when compared with sal-
meterol [42].3.3.2. Tiotropium monotherapy versus indacaterol
One publication compared tiotropium with indacaterol [29]. In
the second, prespeciﬁed superiority analysis, the annualized rate of
exacerbations was shown to be higher with indacaterol than with
tiotropium (0.90 vs. 0.73; rate ratio [95% CI], 1.24 [1.12e1.37];
p < 0.0001), showing superiority of tiotropium [29]. In addition, the
time to ﬁrst moderate or severe exacerbation was longer with
tiotropium (HR [95% CI], 1.20 [1.07e1.33]; p ¼ 0.0012) over a 1-year
period [29]. The HR and 95% CIs presented here for tiotropium
versus indacaterol for time to ﬁrst moderate or severe exacerbation
were derived by inverting the HRs and CIs reported in the refer-
enced publication (HR [95% CI], 0.83 [0.75e0.93]; p ¼ 0.0012)
(Fig. 3; online supplement, Table E3).
In a separate subgroup analysis of patients with exacerbations
treated with ICS and/or antibiotics, exacerbation rates were higher
in the indacaterol group than in the tiotropium group [29]. How-
ever, in patients stratiﬁed by ICS at baseline, the rates of severe
exacerbations were not signiﬁcantly different between the two
groups. Overall, fewer patients in the tiotropium group experienced
an exacerbation during the study than those in the indacaterol
group.
Fig. 3. Hazard ratios for an exacerbation of COPD in patients receiving tiotropium versus an active comparator. a Reciprocal HR and 95% CI for tiotropium versus tiotropium plus
ﬂuticasone-salmeterol were derived and not as reported in the Aaron et al., 2007 [21] (the reported unadjusted of HR [95% CI], 0.80 [0.60e1.08] are inconsistent with the results
presented in the text and are therefore a likely error in the original publication [21]); b The reciprocal HR and 95% CIs for tiotropium versus active comparator were derived and not
statistically reported in the original publications where values for active comparator versus tiotropium were given.
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Six publications compared tiotropium with dual (either LABA/
LAMA or LABA/ICS) and/or triple therapy (online supplement,
Table E3) [19e21,33,43,44].
The Effect of QVA149 Versus NVA237 and Tiotropium on COPD
Exacerbations (SPARK) study compared tiotropium versus a combi-
nation of glycopyrronium 50 mg/indacaterol 110 mg (QVA149) and
glycopyrronium alone (NVA237) in patients at risk of an exacerbation
[44]. Overall, the incidence of severe exacerbations was low, with no
signiﬁcant differences observed between tiotropium and the glyco-
pyrronium/indacaterol combination; however, in patients receiving
glycopyrronium alone, there was an increase in severe exacerbations
compared with tiotropium (rate ratio [95% CI], 1.43 [1.05e1.97];
p ¼ 0.025; online supplement, Table E3). The rate of moderate or
severe exacerbations was not signiﬁcantly lower with the glyco-
pyrronium/indacaterol combination versus tiotropium (rate ratio
[95% CI], 0.90 [0.79e1.02]; p ¼ 0.10), nor with glycopyrronium alone
versus tiotropium (rate ratio [95% CI], 1.03 [0.91e1.16]; p ¼ 0.68).
Two publications reporting three studies compared the LAMA/
LABA combination of umeclidinium/vilanterol with tiotropium
[19,20]. In one 24-week blinded study, in which the time to ﬁrst
COPD exacerbation event was an additional endpoint, the risk of an
exacerbation was reduced with the LAMA/LABA combination
compared with tiotropium (HR [95% CI], 0.5 [0.3e1.0]; p ¼ 0.044);
however, the number of patients with events was low in both
treatment groups (n ¼ 16 [4%] vs. 29 [6%], respectively) [20].
Furthermore, a numerically greater proportion of patients who
experienced an exacerbation were receiving additional ICS treat-
ment in the umeclidinium/vilanterol group (n ¼ 12 [75%])
compared with tiotropium (n ¼ 20 [69%]) [20]. In contrast, in two
other blinded studies, the risk of a COPD exacerbation was
numerically higher in the umeclidinium/vilanterol group whencompared with tiotropium, though these results were not signiﬁ-
cant (HR [95% CI], 1.2 [0.5e2.6]; p ¼ 0.71; and HR [95% CI], 1.9
[1.0e3.6]; p ¼ 0.06, respectively) [19].
When compared with the salmeterol plus ﬂuticasone combi-
nation, tiotropium was not associated with signiﬁcant differences
either in the rate of exacerbations (rate ratio [95% CI], 0.97
[0.84e1.12]; p ¼ 0.656) or the rate of hospitalizations (13% vs. 16%;
p ¼ 0.085) in patients with COPD and a clinical history of exacer-
bations (online supplement, Table E3) [43]. In a second study, there
were no signiﬁcant differences in exacerbation rates with tio-
tropium plus salmeterol/ﬂuticasone combination versus tio-
tropium alone (p ¼ 0.531) (online supplement, Table E3) [33].
In a multicenter trial of patients with moderate or severe COPD
who had at least one exacerbation treated with corticosteroids or
antibiotics in the 12 months prior to randomization [21], neither
dual therapy with tiotropium and salmeterol, nor triple therapy
with tiotropium, salmeterol, and ﬂuticasone, was associated with
any signiﬁcant differences in the proportion of patients experi-
encing at least one exacerbation, time to ﬁrst exacerbation event, or
mean number of exacerbations when compared with tiotropium
alone. However, unlike dual therapy, triple therapy was associated
with a signiﬁcant reduction in the rate of severe exacerbations
requiring hospitalization compared with tiotropium monotherapy
(relative risk, 0.53; p ¼ 0.01) (online supplement, Table E3).
3.4. Additional information from open-label comparisons
3.4.1. Tiotropium monotherapy versus glycopyrronium and placebo
One publication compared open-label tiotropium with glyco-
pyrronium bromide [44,45], and another compared each agent
with placebo [45].
In the SPARK study, when tiotropium was compared with
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annual rates of moderate or severe exacerbations (0.93 vs. 0.95) or
severe exacerbations (0.08 vs. 0.12) [44].
In a 1-year open-label study, tiotropium reduced the risk of
exacerbations (time to ﬁrst moderate or severe exacerbation) by
34% compared with placebo (HR [95% CI], 0.66 [0.52e0.85];
p ¼ 0.001) [45]. The risk reduction was 39% with glycopyrronium
versus placebo (HR [95% CI], 0.61 [0.46e0.82]; p ¼ 0.001). While
glycopyrronium was associated with a 35% reduction in the rate of
moderate or severe exacerbations compared with placebo (0.54 vs.
0.80; rate ratio [95% CI], 0.66 [0.50e0.87]; p ¼ 0.003), the effect of
tiotropium was not signiﬁcantly different from placebo (rate ratio
[95% CI], 0.80 [0.59e1.11]; p ¼ 0.179). Both glycopyrronium and
tiotropium were superior to placebo in reducing moderate exac-
erbations treated with systemic corticosteroids (odds ratio [95% CI],
0.61 [0.43e0.87; p ¼ 0.006 and 0.62 [0.41e0.93]; p ¼ 0.021,
respectively) or antibiotics (odds ratio [95% CI], 0.69 [0.50e0.96];
p ¼ 0.026 and 0.65 [0.44e0.95]; p ¼ 0.026, respectively) [45].
3.4.2. Tiotropium monotherapy versus indacaterol and placebo
One publication compared open-label tiotropium with indaca-
terol and placebo [46]. Over 26 weeks, tiotropium was associated
with numerical reductions in exacerbations versus placebo (HR
[95% CI], 0.76 [0.56e1.03]; p ¼ 0.080) but did not signiﬁcantly
reduce the rate of exacerbations compared with placebo (rate ratio
[95% CI], 0.70 [0.48e1.03]; p¼ 0.070). Indacaterol 150 mg did appear
to have a signiﬁcant beneﬁt over placebo in terms of time to ﬁrst
COPD exacerbation (HR [95% CI], 0.69 [0.51e0.94]; p ¼ 0.019) and
the rate of exacerbations (rate ratio [95% CI], 0.67 [0.46e0.99];
p ¼ 0.044) in this study.
4. Discussion
Clinicians need clear advice from guidelines and initiatives such
as GOLD on the best ﬁrst-choice therapies for managing patients
with COPD, particularly when considering outcomes such as effects
on exacerbation rates. Tiotropium is the most widely studied LAMA
and, as such, there is a considerable amount of data available.
However, to our knowledge, this is the ﬁrst systematic review of all
published randomized, controlled trials designed to assess exac-
erbations outcomes (as prespeciﬁed endpoints) in patients
with COPD who were receiving tiotropium via HandiHaler® or
Respimat® (compared with placebo and/or other maintenance
therapies).
Overall, tiotropium appears to be associated with a longer time
to ﬁrst exacerbation event and fewer exacerbations (including se-
vere exacerbations/hospitalizations) than either placebo or active
comparator treatment. To date, there are limited data available to
suggest an additional clinical beneﬁt (in terms of exacerbation
reduction) when using LAMA/LABA combinations or a LABA/ICS in
combination with a LAMA.
Generally, exacerbation outcomes were comparable with both
formulations of tiotropium (HandiHaler® 18 mg/Respimat® 5 mg), a
ﬁnding in line with evidence from the TIOtropium Safety and Per-
formance In Respimat® (TIOSPIR®) study (N ¼ 17,135), which
demonstrated similar exacerbation efﬁcacy and safety proﬁles for
the two formulations [47].
Both LAMAs and LABAs are effective treatments for patients
with COPD and are widely used in clinical practice; however, dif-
ferences in exacerbation outcomes between various treatments
have been demonstrated in the literature. For example, tiotropium,
a once-daily LAMA, signiﬁcantly decreased the annual rate of ex-
acerbations for patients with moderate to very severe COPD
compared with salmeterol, a twice-daily LABA [15]. A trend for
lower rates of exacerbations was evident with tiotropiumcompared with indacaterol, a once-daily LABA [29], and indacaterol
did not show non-inferiority to tiotropium in terms of the annual
rate of exacerbations. These ﬁndings indicate that tiotropium may
be more effective than LABAs in terms of exacerbation reduction,
irrespective of once-daily or twice-daily regimens, suggesting that
the effect is not simply related to sustained bronchodilation. It has
been postulated that differences in duration and mechanism of
action may account for their exacerbation outcome proﬁles; how-
ever, evidence is currently lacking and further prospective, ran-
domized studies are needed to compare directly the exacerbation
efﬁcacy of these agents.
Potential mechanisms that may contribute to the preventive
effects of tiotropium on COPD exacerbations might include inhi-
bition of the action of acetylcholine in the lung, which may lead to
suppression of acetylcholine-mediated release of chemotactic
substances involved in the modulation of inﬂammatory responses
[48]. Inhibition of acetylcholine may translate into additional ef-
fects beyond that of bronchodilation (i.e., anti-inﬂammatory ef-
fects), and the reduction of proliferation and mucus secretion
[48e51].
Although beyond the scope of this review, an important clinical
question is whether the exacerbation-prevention properties of
tiotropium can be considered a class effect. While LAMAs all
demonstrate a high afﬁnity and potency toward the muscarinic M3
receptor, tiotropium has been shown to have a much longer
dissociation from the receptors than either aclidinium or glyco-
pyrronium [50,52]. Tiotropium therefore provides an effective and
long-lasting (>24 h) blockade of the M3 receptors [53,54]. In line
with these kinetic properties, preclinical data suggest that tio-
tropium should provide the greatest level of bronchoprotection of
all three LAMAs when applied at equieffective doses [50]. It is
speculative as to whether LAMAs have anti-inﬂammatory effects:
most of the studies suggesting that LAMAs have anti-inﬂammatory
and anti-remodelling properties have been conducted in vitro, and
clinical studies showing deﬁnite anti-inﬂammatory activity for any
LAMA are lacking. Few studies have directly compared the exac-
erbation efﬁcacy of LAMAs, and this is worthy of further
investigation.
Unlike LAMAs, which mediate their bronchodilator effects
through inhibition of cholinergic pathways, LABAs mediate their
effects, in part, through stimulation of b2-adrenergic receptors.
Recent studies suggest that genetic variation in these receptorsmay
play an important role in treatment response [55], with some ge-
notypes associated with a limited response to b2-adrenergic drugs
and others a full response; however, in clinical practice these ge-
notypes are difﬁcult to identify.
There are both strengths and limitations of this systematic re-
view that should be considered when evaluating the ﬁndings. A
total of 29 publications were selected for review, including large
studies that were speciﬁcally powered to evaluate exacerbations
[12,15,47], and studies that were large and of a long enough dura-
tion to evaluate exacerbations in subgroup analyses [14,15]. In
terms of limitations, the results are generally reported in a
descriptive manner, and direct comparisons between trials are not
conclusive due to differences in study designs and other potential
methodological shortcomings. The lack of standardization in end-
points and outcomes between trials precluded the ability to pool
data from different studies and perform a formal meta-analysis of
the exacerbation data. Deﬁnitions used to describe an exacerbation
event, including severity, differed between trials, and it is unknown
whether these differences may have inﬂuenced results; however,
there appears to be consistency in the results of the individual
studies reviewed here.
Since our search was restricted to English-language papers and
mainstream journals (electronic search of the main databases), we
D.M.G. Halpin et al. / Respiratory Medicine 114 (2016) 1e8 7cannot discount the possibility that some studies may have been
excluded from this review; however, due to the comprehensive and
rigorous literature search process, we are conﬁdent that all key
studies published at the time were captured and included.
Although not all studies were powered to show differences in
exacerbation outcomes, current evidence indicates that tiotropium
appears to demonstrate beneﬁts over placebo and the LABAs sal-
meterol and indacaterol, while providing results comparable with
the LAMA glycopyrronium and the ﬁxed LAMA/LABA combination
QVA149 (glycopyrronium/indacaterol).
Conﬂicts of interest
DMGH has received personal fees and non-ﬁnancial support
from AstraZeneca, Boehringer Ingelheim and Novartis, and per-
sonal fees from GlaxoSmithKline and Pﬁzer. CV has received per-
sonal fees fromAlmirall, AstraZeneca, Boehringer Ingelheim, Chiesi,
Cytos, GlaxoSmithKline, Janssen, Mundipharma, Novartis and
Takeda, and grants and personal fees from Grifols. MPP and NM are
employees of Boehringer Ingelheim. FR was an employee of
Boehringer Ingelheim at the time of manuscript submission. AA has
received personal fees from AstraZeneca, Bayer-Schering Pharma,
Boehringer Ingelheim, Dey Pharma, GlaxoSmithKline and Pﬁzer.
Acknowledgements and funding
Writing assistance was provided by Leigh Prevost and Natalie
Dennis from PAREXEL, which was funded by Boehringer Ingelheim.
All authors contributed to drafting the article and critically
revising the content of the manuscript, and made the decision to
submit this work for publication. All authors read and approved the
ﬁnal manuscript.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.rmed.2016.02.012
References
[1] Global Initiative for Chronic Obstructive Lung Disease, Global Strategy for the
Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary
Disease: Updated, 2015. GOLDCOPD website. Available at: http://www.
goldcopd.org/uploads/users/ﬁles/GOLD_Report_2015.pdf (accessed
20.03.2015).
[2] P.W. Jones, J.F. Donohue, J. Nedelman, S. Pascoe, G. Pinault, C. Lassen, Corre-
lating changes in lung function with patient outcomes in chronic obstructive
pulmonary disease: a pooled analysis, Respir. Res. 12 (2011) 161.
[3] B.R. Celli, P.J. Barnes, Exacerbations of chronic obstructive pulmonary disease,
Eur. Respir. J. 29 (6) (2007) 1224e1238.
[4] J.J. Soler-Cataluna, M.A. Martinez-Garcia, S.P. Roman, E. Salcedo, M. Navarro,
R. Ochando, Severe acute exacerbations and mortality in patients with chronic
obstructive pulmonary disease, Thorax 60 (11) (2005) 925e931.
[5] S.D. Ramsey, S.D. Sullivan, The burden of illness and economic evaluation for
COPD, Eur. Respir. J. Suppl. 41 (2003) 29se35s.
[6] J.R. Hurst, J. Vestbo, A. Anzueto, N. Locantore, H. Mullerova, R. Tal-Singer, et al.,
Susceptibility to exacerbation in chronic obstructive pulmonary disease,
N. Engl. J. Med. 363 (12) (2010) 1128e1138.
[7] S. Spencer, P.M. Calverley, P.S. Burge, P.W. Jones, Impact of preventing exac-
erbations on deterioration of health status in COPD, Eur. Respir. J. 23 (5)
(2004) 698e702.
[8] G.C. Donaldson, T.A. Seemungal, A. Bhowmik, J.A. Wedzicha, Relationship
between exacerbation frequency and lung function decline in chronic
obstructive pulmonary disease, Thorax 57 (10) (2002) 847e852.
[9] P. Montuschi, Pharmacological treatment of chronic obstructive pulmonary
disease, Int. J. Chron. Obstruct. Pulmon. Dis. 1 (4) (2006) 409e423.
[10] Global Initiative for Chronic Obstructive Lung Disease, Global Strategy for the
Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary
Disease: Updated, 2016. GOLDCOPD website. Available at: http://www.
goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html
(Accessed 17.02.16).
[11] C. Karner, J. Chong, P. Poole, Tiotropium versus placebo for chronic obstructivepulmonary disease, Cochrane Database Syst. Rev. 7 (2012) CD009285.
[12] E.D. Bateman, D. Tashkin, N. Siafakas, R. Dahl, L. Towse, D. Massey, et al.,
A one-year trial of tiotropium Respimat plus usual therapy in COPD patients,
Respir. Med. 104 (10) (2010) 1460e1472.
[13] C.B. Cooper, B.R. Celli, J.R. Jardim, R.A. Wise, D. Legg, J. Guo, et al., Treadmill
endurance during 2-year treatment with tiotropium in patients with COPD: a
randomized trial, Chest 144 (2) (2013) 490e497.
[14] D.P. Tashkin, B. Celli, S. Senn, D. Burkhart, S. Kesten, S. Menjoge, et al., A 4-year
trial of tiotropium in chronic obstructive pulmonary disease, N. Engl. J. Med.
359 (15) (2008) 1543e1554.
[15] C. Vogelmeier, B. Hederer, T. Glaab, H. Schmidt, M.P. Rutten-van Molken,
K.M. Beeh, et al., Tiotropium versus salmeterol for the prevention of exacer-
bations of COPD, N. Engl. J. Med. 364 (12) (2011) 1093e1103.
[16] Boehringer Ingelheim Limited, Summary of Product Characteristics (SPC):
Spiriva 18 Microgram Inhalation Powder, Hard Capsule, 2015 emcþ website.
Available at: http://www.medicines.org.uk/emc/medicine/10039/SPC/
Spirivaþ18þmicrogramþinhalationþpowder%2cþhardþcapsule/ (Accessed
01.02.15).
[17] Boehringer Ingelheim Limited, Summary of Product Characteristics (SPC):
Spiriva Respimat 2.5 Microgram Inhalation Solution, 2015 emcþ website.
Available at: http://www.medicines.org.uk/emc/medicine/20134/SPC
(Accessed 01.01.15).
[18] S. Burge, J.A. Wedzicha, COPD exacerbations: deﬁnitions and classiﬁcations,
Eur. Respir. J. Suppl. 41 (2003) 46se53s.
[19] M. Decramer, A. Anzueto, E. Kerwin, T. Kaelin, N. Richard, G. Crater, et al.,
Efﬁcacy and safety of umeclidinium plus vilanterol versus tiotropium, vilan-
terol, or umeclidinium monotherapies over 24 weeks in patients with chronic
obstructive pulmonary disease: results from two multicentre, blinded, rand-
omised controlled trials, Lancet Respir. Med. 2 (6) (2014) 472e486.
[20] M.R. Maleki-Yazdi, T. Kaelin, N. Richard, M. Zvarich, A. Church, Efﬁcacy and
safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in
chronic obstructive pulmonary disease: results of a 24-week, randomized,
controlled trial, Respir. Med. 108 (12) (2014) 1752e1760.
[21] S.D. Aaron, K.L. Vandemheen, D. Fergusson, F. Maltais, J. Bourbeau,
R. Goldstein, et al., Tiotropium in combination with placebo, salmeterol, or
ﬂuticasone-salmeterol for treatment of chronic obstructive pulmonary dis-
ease: a randomized trial, Ann. Intern. Med. 146 (8) (2007) 545e555.
[22] R. Abrahams, P. Moroni-Zentgraf, J. Ramsdell, H. Schmidt, E. Joseph, J. Karpel,
Safety and efﬁcacy of the once-daily anticholinergic BEA2180 compared with
tiotropium in patients with COPD, Respir. Med. 107 (6) (2013) 854e862.
[23] E. Bateman, D. Singh, D. Smith, B. Disse, L. Towse, D. Massey, et al., Efﬁcacy and
safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies,
Int. J. Chron. Obstruct. Pulmon. Dis. 5 (2010) 197e208.
[24] V. Brusasco, R. Hodder, M. Miravitlles, L. Korducki, L. Towse, S. Kesten, Health
outcomes following treatment for six months with once daily tiotropium
compared with twice daily salmeterol in patients with COPD, Thorax 58 (5)
(2003) 399e404.
[25] R. Casaburi, D.A. Mahler, P.W. Jones, A. Wanner, P.G. San, R.L. ZuWallack, et al.,
A long-term evaluation of once-daily inhaled tiotropium in chronic obstruc-
tive pulmonary disease, Eur. Respir. J. 19 (2) (2002) 217e224.
[26] C.K. Chan, F. Maltais, C. Sigouin, J.M. Haddon, G.T. Ford, A randomized
controlled trial to assess the efﬁcacy of tiotropium in Canadian patients with
chronic obstructive pulmonary disease, Can. Respir. J. 14 (8) (2007) 465e472.
[27] M. Decramer, B. Celli, S. Kesten, T. Lystig, S. Mehra, D.P. Tashkin, Effect of
tiotropium on outcomes in patients with moderate chronic obstructive pul-
monary disease (UPLIFT): a prespeciﬁed subgroup analysis of a randomised
controlled trial, Lancet 374 (9696) (2009) 1171e1178.
[28] M. Decramer, G. Molenberghs, D. Liu, B. Celli, S. Kesten, T. Lystig, et al., Pre-
mature discontinuation during the UPLIFT study, Respir. Med. 105 (10) (2011)
1523e1530.
[29] M.L. Decramer, K.R. Chapman, R. Dahl, P. Frith, G. Devouassoux, C. Fritscher, et
al., Once-daily indacaterol versus tiotropium for patients with severe chronic
obstructive pulmonary disease (INVIGORATE): a randomised, blinded,
parallel-group study, Lancet Respir. Med. 1 (7) (2013) 524e533.
[30] D. Dusser, M.L. Bravo, P. Iacono, The effect of tiotropium on exacerbations and
airﬂow in patients with COPD, Eur. Respir. J. 27 (3) (2006) 547e555.
[31] Y. Fukuchi, L. Fernandez, H.P. Kuo, A. Mahayiddin, B. Celli, M. Decramer, et al.,
Efﬁcacy of tiotropium in COPD patients from Asia: a subgroup analysis from
the UPLIFT trial, Respirology 16 (5) (2011) 825e835.
[32] N.A. Hanania, A. Sharafkhaneh, B. Celli, M. Decramer, T. Lystig, S. Kesten, et al.,
Acute bronchodilator responsiveness and health outcomes in COPD patients
in the UPLIFT trial, Respir. Res. 12 (2011) 6.
[33] N.A. Hanania, G.D. Crater, A.N. Morris, A.H. Emmett, D.M. O'Dell,
D.E. Niewoehner, Beneﬁts of adding ﬂuticasone propionate/salmeterol to
tiotropium in moderate to severe COPD, Respir. Med. 106 (1) (2012) 91e101.
[34] A.H. Morice, B. Celli, S. Kesten, T. Lystig, D. Tashkin, M. Decramer, COPD in
young patients: a pre-speciﬁed analysis of the four-year trial of tiotropium
(UPLIFT), Respir. Med. 104 (11) (2010) 1659e1667.
[35] D.E. Niewoehner, K. Rice, C. Cote, D. Paulson, J.A. Cooper Jr., L. Korducki, et al.,
Prevention of exacerbations of chronic obstructive pulmonary disease with
tiotropium, a once-daily inhaled anticholinergic bronchodilator: a random-
ized trial, Ann. Intern. Med. 143 (5) (2005) 317e326.
[36] D.J. Powrie, T.M. Wilkinson, G.C. Donaldson, P. Jones, K. Scrine, K. Viel, et al.,
Effect of tiotropium on sputum and serum inﬂammatory markers and exac-
erbations in COPD, Eur. Respir. J. 30 (3) (2007) 472e478.
D.M.G. Halpin et al. / Respiratory Medicine 114 (2016) 1e88[37] K.L. Rice, I. Leimer, S. Kesten, D.E. Niewoehner, Responses to tiotropium in
African-American and Caucasian patients with chronic obstructive pulmonary
disease, Transl. Res. 152 (2) (2008) 88e94.
[38] Y. Tang, D. Massey, N.S. Zhong, Evaluation of the efﬁcacy and safety of tio-
tropium bromide (5 microg) inhaled via Respimat in Chinese patients with
chronic obstructive pulmonary disease, Chin. Med. J. Engl. 126 (19) (2013)
3603e3607.
[39] D. Tashkin, B. Celli, S. Kesten, T. Lystig, M. Decramer, Effect of tiotropium in
men and women with COPD: results of the 4-year UPLIFT trial, Respir. Med.
104 (10) (2010) 1495e1504.
[40] A.B. Tonnel, T. Perez, J.M. Grosbois, C. Verkindre, M.L. Bravo, M. Brun, Effect of
tiotropium on health-related quality of life as a primary efﬁcacy endpoint in
COPD, Int. J. Chron. Obstruct. Pulmon. Dis. 3 (2) (2008) 301e310.
[41] T. Troosters, B. Celli, T. Lystig, S. Kesten, S. Mehra, D.P. Tashkin, et al., Tio-
tropium as a ﬁrst maintenance drug in COPD: secondary analysis of the
UPLIFT trial, Eur. Respir. J. 36 (1) (2010) 65e73.
[42] C. Vogelmeier, L.M. Fabbri, K.F. Rabe, K.M. Beeh, H. Schmidt, N. Metzdorf, et al.,
Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and mainte-
nance therapy naive patients, Respir. Med. 107 (1) (2013) 75e83.
[43] J.A. Wedzicha, P.M. Calverley, T.A. Seemungal, G. Hagan, Z. Ansari,
R.A. Stockley, The prevention of chronic obstructive pulmonary disease ex-
acerbations by salmeterol/ﬂuticasone propionate or tiotropium bromide, Am.
J. Respir. Crit. Care Med. 177 (1) (2008) 19e26.
[44] J.A. Wedzicha, M. Decramer, J.H. Ficker, D.E. Niewoehner, T. Sandstrom,
A.F. Taylor, et al., Analysis of chronic obstructive pulmonary disease exacer-
bations with the dual bronchodilator QVA149 compared with glycopyrronium
and tiotropium (SPARK): a randomised, double-blind, parallel-group study,
Lancet Respir. Med. 1 (3) (2013) 199e209.
[45] E. Kerwin, J. Hebert, N. Gallagher, C. Martin, T. Overend, V.K. Alagappan, et al.,
Efﬁcacy and safety of NVA237 versus placebo and tiotropium in patients with
COPD: the GLOW2 study, Eur. Respir. J. 40 (5) (2012) 1106e1114.
[46] J.F. Donohue, C. Fogarty, J. Lotvall, D.A. Mahler, H. Worth, A. Yorgancioglu, et
al., Once-daily bronchodilators for chronic obstructive pulmonary disease:indacaterol versus tiotropium, Am. J. Respir. Crit. Care Med. 182 (2) (2010)
155e162.
[47] R.A. Wise, A. Anzueto, D. Cotton, R. Dahl, T. Devins, B. Disse, et al., Tiotropium
Respimat inhaler and the risk of death in COPD, N. Engl. J. Med. 369 (16)
(2013) 1491e1501.
[48] F. Buhling, N. Lieder, U.C. Kuhlmann, N. Waldburg, T. Welte, Tiotropium
suppresses acetylcholine-induced release of chemotactic mediators in vitro,
Respir. Med. 101 (11) (2007) 2386e2394.
[49] E. Sato, S. Koyama, Y. Okubo, K. Kubo, M. Sekiguchi, Acetylcholine stimulates
alveolar macrophages to release inﬂammatory cell chemotactic activity, Am. J.
Physiol. 274 (6 Pt 1) (1998) L970eL979.
[50] P. Casarosa, T. Bouyssou, S. Germeyer, A. Schnapp, F. Gantner, M. Pieper,
Preclinical evaluation of long-acting muscarinic antagonists: comparison of
tiotropium and investigational drugs, J. Pharmacol. Exp. Ther. 330 (2) (2009)
660e668.
[51] G. Pelaia, A. Vatrella, M.T. Busceti, L. Gallelli, C. Calabrese, R. Terracciano, et al.,
Pharmacologic rationale underlying the therapeutic effects of tiotropium/
olodaterol in COPD, Ther. Clin. Risk Manag. 11 (2015) 1563e1572.
[52] C.S. Tautermann, T. Kiechle, D. Seeliger, S. Diehl, E. Wex, R. Banholzer, et al.,
Molecular basis for the long duration of action and kinetic selectivity of tio-
tropium for the muscarinic M3 receptor, J. Med. Chem. 56 (21) (2013)
8746e8756.
[53] K. Alagha, A. Palot, T. Sofalvi, L. Pahus, M. Gouitaa, C. Tummino, et al., Long-
acting muscarinic receptor antagonists for the treatment of chronic airway
diseases, Ther. Adv. Chronic Dis. 5 (2) (2014) 85e98.
[54] A.C. Kruse, J. Li, J. Hu, B.K. Kobilka, J. Wess, Novel insights into M3 muscarinic
acetylcholine receptor physiology and structure, J. Mol. Neurosci. 53 (3)
(2014) 316e323.
[55] K.F. Rabe, L.M. Fabbri, E. Israel, H. Kogler, K. Riemann, H. Schmidt, et al., Effect
of ADRB2 polymorphisms on the efﬁcacy of salmeterol and tiotropium in
preventing COPD exacerbations: a prespeciﬁed substudy of the POET-COPD
trial, Lancet Respir. Med. 2 (1) (2014) 44e53.
